Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial

Weijie Gu, Weiqing Han, Hong Luo, Fangjian Zhou, Dalin He, Lulin Ma, Hongqian Guo, Chang Yin Liang, Tie Chong, Jun Jiang, Zhiwen Chen, Yong Wang, Qing Zou, Ye Tian, Jun Xiao, Jian Huang, Shaoxing Zhu, Qiang Dong, Xiaoping Zhang, Hanzhong Li, Xinfeng Yang, Chunxia Chen, Junliang Li, Chunlei Jin, Xiaojing Zhang, Dingwei Ye